Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital starts coverage of Babcock at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Babcock on Monday with an 'outperform' rating and 1,200p price target. The bank said Babcock is a significantly better-quality business 4.5 years into a turnaround, but its 5x PE (NTM) discount versus the European defence sector fails to capture this.

"Babcock's UK MOD relationship, military operational asset engineering know-how and infrastructure ownership underpins high visibility," RBC said.

"This, combined with a strong management team and execution, now provides strong prospects for success on an attractive hopper of opportunities in the UK and abroad."

RBC said Babcock's management is one of its key strengths. It noted that the team has reduced contract risk, improved earnings quality, and strengthened the balance sheet through disposals.

Babcock now has a 74% defence mix, versus 46% in 2019, RBC said.

"Beat and raise is the mantra, with three earnings upgrades in FY25 and a recently increased mid-term (3-5 year) guidance," it added.

RBC said it views guidance as conservative and sits around 3% ahead on FY26-28 estimated adjusted earnings per share, with potential for upside beyond this.

At 0850 BST, the shares were up 2.2% at 1,017p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.